RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

The mutation of K‐RAS represents one of the most frequent genetic alterations in cancer. Targeting of downstream effectors of RAS, including of MEK and ERK, has limited clinical success in cancer patients with K‐RAS mutations. The reduced sensitivity of K‐RAS‐mutated cells to certain MEK inhibitors...

Full description

Bibliographic Details
Main Authors: Xi Yuan, Zhiyu Tang, Rong Du, Zhan Yao, Shing‐Hu Cheung, Xinwen Zhang, Jing Wei, Yuan Zhao, Yunguang Du, Ye Liu, Xiaoxia Hu, Wenfeng Gong, Yong Liu, Yajuan Gao, Zhiyue Huang, Zongfu Cao, Min Wei, Changyou Zhou, Lai Wang, Neal Rosen, Paul D. Smith, Lusong Luo
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Molecular Oncology
Subjects:
combination therapy
MEK inhibitor
RAF dimer inhibitor
RAS‐mutated cancer
synergy
Online Access:https://doi.org/10.1002/1878-0261.12698

Internet

https://doi.org/10.1002/1878-0261.12698

Similar Items